Online inquiry

IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3444MR)

This product GTTS-WQ3444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, AZD8895(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3444MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9867MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA K7153A
GTTS-WQ13348MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ8434MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA HSP90mab
GTTS-WQ7527MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ13440MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRO95780
GTTS-WQ8528MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ9531MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ2155MR IVTScrip™ mRNA-Anti-IL6, ALD-518(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ALD-518
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW